1. Home
  2. MYE vs ABUS Comparison

MYE vs ABUS Comparison

Compare MYE & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Myers Industries Inc.

MYE

Myers Industries Inc.

HOLD

Current Price

$30.81

Market Cap

1.2B

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$5.00

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MYE
ABUS
Founded
1933
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
1995
2008

Fundamental Metrics

Financial Performance
Metric
MYE
ABUS
Price
$30.81
$5.00
Analyst Decision
Buy
Strong Buy
Analyst Count
1
1
Target Price
$26.00
$5.00
AVG Volume (30 Days)
286.2K
4.9M
Earning Date
05-07-2026
05-14-2026
Dividend Yield
2.71%
N/A
EPS Growth
389.47
55.26
EPS
0.48
0.84
Revenue
N/A
$14,083,000.00
Revenue This Year
$0.87
N/A
Revenue Next Year
$1.83
$239.71
P/E Ratio
$65.48
$6.04
Revenue Growth
N/A
128.21
52 Week Low
$15.54
$3.50
52 Week High
$37.45
$5.45

Technical Indicators

Market Signals
Indicator
MYE
ABUS
Relative Strength Index (RSI) 44.47 51.78
Support Level $29.85 $4.99
Resistance Level $31.62 $5.06
Average True Range (ATR) 1.00 0.08
MACD -0.07 -0.03
Stochastic Oscillator 41.33 11.76

Price Performance

Historical Comparison
MYE
ABUS

About MYE Myers Industries Inc.

Myers Industries Inc designs, manufactures, and markets a variety of plastic, metal, and rubber products, including a broad selection of plastic reusable containers, pallets, small parts bins, bulk shipping containers, storage and organization products, OEM parts, custom plastic products, consumer fuel containers and tanks for water, fuel and waste handling. It operates through the following segments: The Material Handling segment manufactures a selection of durable plastic reusable products that are used repeatedly during the course of their service life. The Distribution segment is engaged in the distribution of equipment, tools, and supplies used for tire servicing and automotive under-vehicle repair, etc. It generates the majority of its revenue from the Material Handling segment.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: